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Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease leading to
decreased lung volume and eventual respiratory failure. At present, the median
post-diagnosis lifespan is between three and six years. Myofibroblasts are
collagen-secreting cells essential for wound healing, but also implicated in the
fibroproliferation and extra cellular matrix deposition commonly seen in IPF. The
nitric oxide (NO) signaling pathway is implicated in protomyofibroblast to
myofibroblast transition and regulation. Previous work has shown that in
pulmonary myofibroblasts, endothelial nitric oxide synthase (eNOS) is the
primary NOS isoform expressed. The current study used cultured rat pulmonary
myofibroblasts between passages two and five as a cell model. The cells were
grown in normal growth media (DMEM + 10% FBS) or serum starved (DMEM +
0% FBS) to induce cellular differentiation. In this study, immunocytochemistry
was used to show localization of eNOS is dependent on cellular differentiation,
with protomyofibroblasts expressing eNOS primarily in the nucleus and
protomyofibroblasts expressing eNOS in the perinuclear region. We also show
catalytic activity and localization of eNOS are correlated by visualizing nitric oxide
production in the cells using a permeable fluorescein chromophore. By using
western blot analysis on fractionated cell lysates we found eNOS expressed in
vii

the nucleus under normal growth conditions. eNOS is at least partially regulated
by intracellular calcium (Ca2+) and calmodulin (CaM). Western blot analysis using
native eNOS and phospho-specific eNOS antibodies on fractionated cells treated
with the protein kinase C (PKC) activator phorbal 12-myristate 13-acetate (PMA)
with and without addition of its antagonist ethylene glycol tetraacetic acid (EGTA)
was conducted to investigate PKC’s role in eNOS regulation by phosphorylation.
Indeed, PKC activation was found to mitigate expression in the nucleus, while
inhibition of the activator restored the activity expression above basal levels. This
finding correlates with previous data from our lab showing a decrease in activity
in myofibroblasts treated with PMA and assayed amperometrically with an NO
electrode.

viii

INTRODUCTION

Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is characterized by actively proliferating
myofibroblasts and a subsequent uncontrolled release of extracellular matrix
(ECM) proteins in pulmonary tissue, driving the destruction of the lung
parenchyma architecture (Selman et al., 2001). Exertional dyspnea and chronic
cough account for around 90% of the initial symptoms, and diagnostic
confirmation is typically performed via a lung biopsy and chest radiographs,
which show bilateral peripheral based reticular opacities and honeycombing
predominately in the lower lobes (Figure 1). The American Thoracic Society and
European Respiratory Society established international guidelines in 1999
regarding the diagnostic criteria that must be present for the confirmation of IPF.
Briefly, a definitive diagnosis can be established in the presence of a surgical
biopsy that includes the following:
1. Exclusions of other known causes of interstitial lung disease such as drug
toxicities, environmental exposures, and collagen vascular diseases
2. Abnormal pulmonary function studies that include evidence of restriction
and/or impaired gas exchange with rest or exercise or decreased carbon
dioxide diffusing capacity of the lung
3. Abnormalities on conventional chest radiographs or high-resolution
computed tomography scans (IPF: Diagnosis and Treatment 1999)
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Figure 1: (A) Normal lung radiograph (BMJ publishing group, 2002). (B)
Radiograph of patient with IPF. Bilateral scarring and honeycombing is prominent
(Heilman, 2010)
Prevalence based on a cohort study from the years 1996 to 2000 was
found to range from 4.0 per 100,000 persons aged 18-34 years to 227.2 per
100,000 persons among those 75 years and older (Raghu et al., 2006).
Prognosis for those suffering from IPF, while displaying a fairly large
heterogeneity depending on the time of diagnosis and subsequent treatment, is
generally poor, with a post-diagnosis life span of three to six years (Bjoraker et
al., 1998; Johnston et al., 1997; Gay et al., 1998).
IPF is thought to be a deleterious consequence of unresolved pulmonary
inflammation that can be stimulated from various causative agents, including
preexisting disease, acute illness and injury. Normally, patients are treated with
anti-inflammatory therapies and show improvement in the days to weeks
following diagnosis. However, a small number of these patients will progress
towards chronic fibrosis, eventually showing the excessive ECM deposition and
honeycombing of the lung. Patients presenting with IPF only respond mildly at
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best to treatment with anti-inflammatory agents such as corticosteroids (Selman
et al., 2002). It should be noted, however, that early in vivo characteristics of IPF
show similarities to non-pathogenic usual interstitial pneumonia (UIP), so much
so, in fact, that early stage identification of IPF cannot be readily distinguished
from UIP (Nicholson et al., 2000). The unfortunate distinction that separates
patients suffering from true IPF from those with UIP is death following the lack of
physiological response to currently accepted treatment measures with high dose
corticosteroids, such as prednisone and a supplemental cytotoxic
immunosuppresent (Rhagu, 2006; Rudd et al., 1981; Johnston et al., 1991). This
resistance to conventional treatment demands investigation into alternative
therapeutic targets.

Cell biology of the myofibroblast
As a primitive mesenchyme-derived cell, myofibroblasts are a key part of
normal tissue development. The initial identification of the myofibroblast came via
electron microscopy, and was seen in the granulation tissue of healing wounds
as a modulated fibroblast (Desmoulière & Gabbiani, 1996). This fibroblast-like
cell exhibited features of smooth muscle cells, including bundles of
microfilaments with dense bodies scattered in between and gap junctions
(Desmouliere et al., 2007). Myofibroblastic modulation of fibroblastic cells begins
with the appearance of the protomyofibroblast. Differentiation from
protomyofibroblast to myofibroblast is characterized by the expression of alphasmooth muscle actin (α-SMA) in the cell. The appearance of these
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microfilaments with dense bodies suggests that myofibroblasts are responsible
for the production of the force causing wound contraction (Desmouliere &
Gabbiani, 1996). The mechanism behind the further modification of the
protomyofibroblast to myofibroblast is not well known, but evidence has been
shown correlating the differentiation with the production of transforming growth
factor-beta (TGF-β) by inflammatory cells as well as products of other fibroblasts
(See Figure 2) (Desmouliere et al., 1993). In the lung in particular, they play an
important role in alveolar development and are necessary for the proper repair of
tissues during wound healing and general tissue homeostasis (Walker, et al
2000). During wound healing, repair takes place in a well known, linear fashion:
clots form, inflammatory cells invade injured tissues, fibroblasts migrate and
begin the proliferation of extracellular matrix (ECM) components, the wound
closes and, following the degradation of ECM, a scar forms (Desmoulière &
Gabbinani, 1996).
While myofibroblasts are typically identified by α-SMA expression,
expression of other sarcomeric proteins should be considered for their role in the
myofibroblast’s contractile funtions. Rice and Leinwand (2003) demonstrated
that pulmonary myofibroblasts express three of the six skeletal isoforms of heavy
chain myosin, including two adult isoforms, IIa and IId, and the developmental
embryonic isoform. Inhibition of skeletal myosin activity significantly reduces
contractile ability in the myofibroblast, an essential function in their ability to
generate tensile forces in wound healing and contracture (Rice & Leinwand,
2003).
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Figure 2: Fibroblast to myofibroblast transition (Adapted from Desmoulière et al.,
2005)

The myofibroblast and IPF
In 1991, Kuhn and McDonald observed a matrix of fibronectin-containing
fibrils, and among them myofibroblasts with well-formed actin filament bundles in
biopsied lung tissue of seven patients suffering from usual interstitial pneumonia
or bronchiolitis obliterans organizing pneumonia. These fibronectin-containing
fibrils linked cells and collagen bundles and were structurally similar to the
contractile phase seen in wound healing. This provided evidence that active
fibroblast contraction plays a role in the remodeling lung tissue during pulmonary
fibrosis (Kuhn & McDonald, 1991).
Further evidence of the fibroblast/myofibroblast role in IPF has been
demonstrated by microarray analysis of pulmonary tissue from bleomycininduced fibrotic mice. A drastic increase was noted in genes expressing
5

inflammatory mediators, components of the ECM and transforming growth factorβ1 (TGF-β1). The murine evidence was taken into consideration in the further
identification of increased gene expression among tissue samples taken from five
patients afflicted with IPF. In correlation with the IPF animal model, genes
encoding proteins expressed in smooth muscle differentiation and muscle
contractile machinery were identified in the samples, representing transcriptional
signals of myofibroblasts and fibroblasts in the myofibroblast/fibroblast foci
typically seen in the disease. Also observed was an increased transcription of
genes encoding ECM proteins in fibrotic lungs (Kaminski, IPF supplement 2003).
Histologically, IPF is distinct from other idiopathic interstitial pneumonias in
that it is a temporally heterogeneous disease. Temporal heterogeneity indicates
various levels of injury within the same tissue biopsy, as opposed to temporal
homogeneity, in which the age of lung injury is approximately the same in each
tissue sample. Biopsies of IPF-associated lung tissues exhibit interstitial collagen
accumulation in the same specimen where there is end-stage honeycomb lung
(chronic injury) and active fibrosis (acute injury). The fibroblasts present in the
actively proliferating fibrotic foci are responsible for ECM deposition,
inflammation, and altered mechanical properties in the fibrotic lesions (Dacic &
Yousem, IPF supplement, 2003). An imbalance between ECM component
production and degradation due to a decrease in normal cellular apoptosis is a
significant problem associated with IPF. Increased ECM remodeling in IPF lungs
has also been found to correlate with imbalances in matrix metalloproteinase
(MMP) family components, notably an increase in tissue inhibitors of
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metalloproteinase (TIMPs) (Ramos et al., 2001). MMPs are responsible for
degradation of ECM components. TIMPs, in their active form, are inhibitors of
MMP catalytic activity. While the process is largely unknown, this is yet further
evidence of the role fibroblasts play in the overproduction of ECM components
and expanse of fibrotic foci.
Zhang and colleagues (1994) found an increase in the amount of
myofibroblasts in bleomycin-induced fibrotic lungs of mice, establishing the
correlation between the amount of actively proliferating myofibroblasts and
increased level of disease (Zhang et al., 1994). This evidence helped establish
the correlation between concentrations of myofibroblasts in their contractile
phase and poorer prognosis in subjects with IPF (King et al., 2001). In normal
tissues, myofibroblasts appear transiently and are responsible for the production
of new collagen and fibronectin at the leading edge of the healing wound.
Myofibroblasts in other forms of organizing pneumonias have been shown to
undergo normal apoptosis, whereas those associated with IPF remain. The
increase in actively proliferating myofibroblasts, the increase in TIMPS, and the
increased production of TGF-β, a known protector against apoptosis, shift focus
of IPF away from a disease of abnormal inflammation to one of abnormal
apoptosis among the myofibroblasts at the fibrotic foci (Phan, 2002).

Nitric oxide signaling
In the late 1980s, the action of nitric oxide (NO) on relaxation of
endothelial cells was elucidated (Palmer et al., 1987). The discovery of NO as a
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signaling molecule led to the 1998 Nobel Prize in Physiology and Medicine. Nitric
oxide is a free radical gas produced from the conversion of L-arginine, molecular
oxygen (O2), and NADPH substrates to L-citrulline and NADP by a group of
proteins known collectively as NO synthases (NOS) (Figure 3). NO synthesis
also requires the presence of four additional cofactors (tetrahydrobiopterin (BH4),
FAD, FMN, and iron protoporphyrin IX (heme)), as well as calmodulin. (Knowles
& Moncada, 1994) The NO produced by the NO synthases diffuses to nearby
smooth-muscle cells and binds to the active site heme of guanylyl cyclase. This
stimulates the enzyme to increase production of cyclic guanidine monophosphate
(cGMP) and ultimately activate cGMP-dependent kinases (Moncada & Higgs,
1993; Knowles & Moncada, 1994). Three major isoforms constitute the NOS
family: - neural NOS (nNOS), inducible NOS (iNOS), and endothelial NOS
(eNOS). These three isoforms are products of different genes, under different
regulation, have different localization properties, catalytic properties, and inhibitor
sensitivity. It should also be noted that the enzymes differ in their constitutive
(eNOS and nNOS) verses inducible (iNOS) expression, as well as their calciumdependence (eNOS and nNOS) or calcium-independence (iNOS) properties
(Alderton et al., 2001). Each NOS exhibits oxygenase and reductase structures
in which an N-terminal oxygenase domain containing binding sites for heme,
BH4, and L-arginine is linked by a calmodulin-dependent recognition site for FAD,
FMN and NADPH. In all isoforms, only dimeric NOSs are catalytically active.
Nitric oxide plays critical roles in vascular biology, including vessel
relaxation and inhibition of platelet aggregation, as well as the regulation of
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endothelial cell death. The loss of levels of bioavailable NO is an important
biochemical marker of early endothelial disfunction found in cardiovascular
diseases such as hypertension and atherosclerosis (Boo & Jo, 2003). Long-term
inhibition of NO production in the heart leads to an increase in αSMA-positive
myofibroblasts with associated collagen and fibronectin deposition in ischemic
lesions (Pessanh et al., 2000). Generally, NO shows anti-fibrotic properties in a
number of diseases by lowering the levels of differentiated myofibroblasts, levels
of injury-inducing reactive oxygen species, and collagen deposition (Vernet et al.,
2002).
The formation of NO from L-arginine and NADH is an important part of
nonspecific host immunity but also has the unique property of aiding in the
maintenance of cell homeostasis (Mohr et al., 1996). There is significant
evidence that NO, either delivered by NO donors or generated by NO synthases,
initiates apoptotic cell death. The influence at which NO facilitates this apoptosis
cascade is dependent on the relative rates of NO formation, its redox state, and
combinations with oxygen, superoxide, and other biomolecules (Brüne et al.,
1999). This evidence suggests a role of NO in the appearance, differentiation,
and disappearance of myofibroblasts at the wound site (Desmouliere et al.,
1995). Zhang and colleagues (1995) reported that pulmonary myofibroblasts are
more susceptible to NO-mediated apoptosis than are undifferentiated fibroblasts
(Zhang et al., 1995).
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Figure 3: The NO synthase reaction. The boxed O and N atoms show the origin
of the constituent atoms of NO (Knowles and Moncada, 1994).

NO signaling and pulmonary myofibroblast accumulation
As discussed briefly above, there is ample support for NO-mediated
regulation of myofibroblast accumulation and ECM deposition. Unfortunately, few
of these studies focus on pulmonary cells. Interestingly, a number of these
studies target the eNOS isoform with myofibroblast activity: Ruetten and
colleagues (2005) generated knockout mice for each of the three NOS isoforms
and demonstrated that eNOS deficient mice have an increase in interstitial
fibrosis related to pressure overload-induced left ventricular hypertrophy (Ruetten
et al., 2005). IPF is frequently associated with pulmonary hypertension
characterized by an increase in mean pulmonary arterial pressure. Vascular
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remodeling of the pulmonary artery is the underlying cause of the pulmonary
hypertension in IPF patients and treatment with the NO synthase stimulating
vascular endothelial growth factor (VEGF) appears to mitigate pulmonary
hypertension by reducing endothelial apoptosis, increasing vascularization, and
reducing pulmonary arterial pressure. However, VEGF treatment also
exacerbates IPF (Farkas et al., 2009). Multiple exposures to bleomycin will
induce chronic fibrosis in mouse (and most likely all mammalian) lungs. eNOS
knockout mice were observed to maintain a prolonged fibrotic foci after multiple
bleomycin exposures, while iNOS knockouts were able to clear the fibrosis as
easily as wildtype mice (Chung et al., 2003).

eNOS activation via phosphorylation
Previous work has demonstrated eNOS activation via sheer stress as an
effect of blood streaming through vascular tissues (Davies, 1995). There has
been ample evidence implicating both an increase or decrease in eNOS catalytic
activity due to phosphorylation of serine/threonine residues in the protein
(Dimmeler et al., 1999; Fulton et al., 1999; Fleming & Busse, 2003). Two
residues in particular, threonine 495 (Thr495) and serine 1177 (Ser1177) (1179 in
bovine-derived eNOS) have been shown to have important roles in the regulation
of eNOS catalytic activity.
Threonine 495 is located in the calmodulin-binding domain of eNOS and
is phosphorylated by a constitutively active AMP-activating kinase or a protein
kinase C (PKC). The catalytic activity of eNOS, notably a decrease in production
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of NO, is associated with Thr495 phosphorylation and is likely explained by the
interference with the binding of CaM to the CaM-binding domain of the eNOS
protein (Fleming & Busse, 2003). Incubation of endothelial cells with the PKC
activator phorbol 12-myristate 13- acetate (PMA) was shown to enhance levels of
Thr495 (Fleming et al., 2001).
While the activity of eNOS was initially described to be dependent upon
the presence of Ca2+, it is now known phosphorylation-induced activity changes
can be accomplished without the direct increase or decrease of Ca2+ levels
(Ayajiki et al., 1996). Fluid shear stress generated by the viscous drag of blood
flowing over the surface of endothelial cells results in the activation of
phosphatidylinositol 3-kinase, which activates Akt and protein kinase A to
phosphorylate eNOS on Ser1177 and results in an increase in eNOS activity
(Dimmeler et al., 1999).
It has been observed that the phosphorylation of eNOS at one site may
affect the phosphorylation at other sites (Bauer et al., 2003). Another serine
residue, Ser635, is a frequently observed phosphorylated residue correlating with
an increase in eNOS activity and often co-phosphorylated with Ser1179.
Investigation using double phospho-mutants of eNOS where both Ser1179 and
Ser635 were mutated to alanine or aspartic acid showed both sites contribute to
the regulation of eNOS activity, although phosphorylation of Ser635 appears to
have greater influence on activity than Ser1179 (Boo et al., 2006).
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eNOS localization and activity
eNOS localization and activity are correlated in many cells types. In
cultured endothelial cells and intact blood vessels, eNOS is found primarily in the
caveolae associated with the cell membrane with activity levels correlating with
translocation to specific intracellular targets (Garçia-Cardeña et al., 1996). In
nephritic tissues, an increase in luminal blood flow in the ascending limb of the
loop of Henle, responsible for increasing urine concentration in mammals,
induced translocation of eNOS from primarily diffused throughout the cell to the
apical membrane. An increase in luminal flow was also observed to increase the
amount of phosphorylated S1179 eNOS, coinciding with an increase in catalytic
activity (Ortiz et al., 2004).
eNOS localization and expression has also been found to be altered in
neoplastic tissues. Increased eNOS staining intensity and decreased staining
frequency was found to correlate with decreased chance of disease-free survival,
and increased cytoplasmic eNOS localization correlated with increased
myometrial invasion (an indication of invasive carcinoma) in a study of 50 cases
of endometrial carcinoma and normal endometrium (Bentz et al., 1997). A similar
correlation between eNOS localization and breast carcinomas (Thomsen et al.,
1995) further implicates the important role NO plays in carcinogenesis.
It is likely that numerous events implicated in the regulation of eNOS
activity- Ca2+/CaM binding, protein-protein interactions, phosphorylation events,
and subcellular localization, are not necessarily independent factors but
coordinated functions ultimately affecting the activity of the enzyme. Subcellular-
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targeted eNOS mutants show variable localization properties depending on the
mutation generated. For example, wild-type eNOS is found in both the plasma
membrane and Golgi complex, while a myristoylation-deficient eNOS mutant
diffuses among the cytoplasm of the cells. This mutant is also unable to produce
NO, while a plasma membrane-targeted mutant produced NO at higher levels
than WT eNOS (Boo et al., 2006).
Changes in levels of intracellular calcium also show a relationship to
changes in localization and activity of eNOS. Treatment of human skin-derived
mast cells with 1 µM of the calcium ionophore A23187 showed moderate
increases in cytoplasmic localization and pronounced increases in nuclear
localization when analyzed via immunofluoresence. Further analysis of phosphospecific eNOS in cells treated with A23187 indicated increased levels of
phospho- Ser1177 eNOS in both the cytoplasmic and nuclear cellular fractions,
suggesting that increased Ca2+ levels potentiate eNOS phosphorylation and,
coordinately, activity (Gilchrest et al., 2004).

Calcium- induced activity changes and activation by PKC
Previous investigations from our lab have focused on myofibroblast
differentiation, eNOS translocation and activtiy, and the cell products implicated
in the regulation of these events. The purpose of the present study was to use
cellular fractionation techniques and immunoblot analysis to test the hypotheses
that localization in pulmonary myofibroblasts is dependent on growth conditions,
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this localization is Ca2+-dependent, and eNOS phosphorylation by PKC regulates
localization and, coordinately, activity.
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MATERIALS AND METHODS

Animals
Four female Lewis rats (4-6 weeks old, 75-100 g) were purchased from
Charles River Laboratories, Willmington MA. All animals were housed in
appropriate biological containment facilities at Western Kentucky University and
work was carried out in accordance with guidelines established by the
Institutional Animal Care and Use Committee (IACUC) and the American
Association for Laboratory Animal Science (AALAS)
(http://www.iacuc.org/usa/htm).

Establishment of primary myofibroblast cell line
The four Lewis rats were euthanized in order to establish a primary cell
line to carry out subsequent work. Pulmonary fibroblasts were isolated as follows:
a tracheal/lung lavage was performed three times with 1x Hank’s Balanced Salt
Solution (HBSS, Invitrogen). The lungs were then gently perfused twice with
saline containing 5 µg/mL heparin. The lungs and heart were dissected out and
moved to a sterile dish containing cold HBSS. Each lung was then dissected free
and placed in cold digestion media (86% 1x HBSS, 0.1% 10x trypsin, 0.02%
DNase, 1 mg/mL collagenase, 0.025% HEPES) where they were minced. Each
minced lung was allowed to incubate at 37˚C+5% CO2 for 30 minutes, and then
was placed in a conical vial and vortexed vigorously for a few seconds.
Dulbecco’s Modified Eagles Media (DMEM, Invitrogen) supplemented with 10%
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(v/v) fetal bovine serum (FBS) and antibiotics (100 U/mL penicillin and 100
mg/mL streptomycin) was added to each tube to halt the digestion. Tissues were
moved to a 100 mm tissue culture dish and macerated with a sterile pipette tip
and transferred back to a 50 mL conical tube. Contents of each tube was
combined and centrifuged three times at 1200 RPM for 10 minutes. Between
each centrifugation, pellets were washed with wash media (DMEM, 5% BCS,
Pen/Strep). Cells were then counted using a hemacytometer and diluted
accordingly for plating at a concentration of 1-2 x 105 cells/100 mm plate. Media
was changed every morning for three to four days following prep to eliminate red
blood cell contamination. After one week, the cells were passaged 1:3.

Cryopreservation of primary myofibroblasts
Cells were grown in DMEM +10% FBS until they reached a concentration
of 1-5 x 106 cells/mL. Cells were then resuspended in 1 mL cryovials of freezing
media (90% FBS + 10% DMSO) at desired concentration and immediately
placed in -80˚C freezer. The vials were transferred to N2 after 24-48 hours.

Myofibroblast culturing
One 1 mL tube containing primary myofibroblasts was removed from N2
and quickly thawed in a 37˚C water bath for 2-3 minutes. Cells were
resuspended 1:10 in normal growth media (DMEM/10%FBS) and gently pipetted
onto a 100 mm dish. Cells were grown to ~70-75% confluence in 37˚C+5% CO2
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incubator, then passaged 1:4 to obtain desired concentration of cells for
experiments. Only cells between passages 2-5 were used for all experiments.

Myofibroblast harvesting and assay
Media was aspirated from each plate containing cells at appropriate
confluence and 1 mL 0.05% trypsin was added and each plate is allowed to
incubate for 30 minutes in 37˚C+5% CO2 incubator enzymatically loosen cells
from the culture dishes. Cells were then washed sterile phosphate-buffered
saline (PBS) and transferred to eppendorf tube, where they were pelleted via
centrifugation and resupended in 1x lysis buffer (10 mM NaCl, 10 mM Tris-HCL
(pH=7.6), 3 mM MgCl2, 0.5% Tween-20) supplemented with protease inhibitor
tablet (Roche). Cells were lysed via sonication (3x pulses, 10 seconds, 60%
amplitude). Protein concentration was obtained via DC protein assay kit (BioRad) or A280 absorbance using a Thermo Nanodrop ND-100 Spectrophotometer
(Stoscheck, 1990).

Nuclear/Cytoplasmic isolation of cell lysates
Fibroblasts were harvested in 5 mL sterile PBS and pelleted via
centrifugation at 2,000 RPM for five minutes at 4°C. Cell lysates were then
resuspended in 1x lysis buffer and allowed to incubate at room temperature for
two minutes, then on ice for 10 minutes. Ten percent NP-40 (Sigma) was added
to the volume of lysates to a final concentration of 1% (v/v) and the solution was
then passed through a 20-gauge needle 2-3 times. One molar MgCl2 was added
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to a final concentration of 5 mM and the nuclei were pelleted by centrifugation at
600g for 5 minutes at 4°C. The cytoplasm-containing supernatant was collected
and centrifuged at 12,000g for 5 minutes at 4°C to ensure no nuclear carryover.
The remaining pellets comprising the nuclear fraction were washed with 300 µl
1x lysis buffer containing 5 mM MgCl2. This wash sequence was repeated 2-3
times, discarding the supernatant each time. The nuclei were lysed by adding
another 300 µl of 1X lysis buffer containing 0.3% sodium dodecyl sulfate (SDS)
to the final wash pellet and vortexing. Nuclear DNA was sheared via sonication
on ice (10 seconds at 50% amplitude). Cytoplasmic and nuclear fractions were
then assayed, aliquoted into working stocks, and stored at -80°C. Adequate
fractionation was confirmed by western blot (see below) by probing with a
proliferating cell nuclear antigen (PCNA) antibody. PCNA is a 35 kDa protein that
accumulates in the nuclei of dividing and transformed cells (Mathews et al.,
1984) and the presence/absence of which confirms successful
nuclear/cytoplasmic fractionation.

SDS-PAGE and Western Blotting
Western blots were carried out using standard methods (Towbin et al.,
1979; Renart et al., 1979) with optimizations for myofibroblast whole-cell lysates.
Briefly, cell lysates were boiled and proteins were separated using SDS-PAGE
with precast 10% polyacrylamide gels (Bio-Rad) suspended in 5x tris/glycine
(125 mM Tris-HCL, 1 M Glycine, 0.5% (w/v) SDS) running buffer. Each lane was
loaded with 25 µL of protein extract, and subsequent analyses were performed
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by normalizing each blot to the concentration of soluble protein loaded. Purified
eNOS (Calbiochem) was used as the positive control for each gel/blot. The gels
were transferred to polyvinyldene fluoride membranes (Fisher) using a semi-dry
transfer apparatus with optimal transfer at 15 V for 30 minutes using a
tris/glycine/methanol transfer buffer (25 mM Tris, 192 mM glycine, 10%
methanol). Each membrane was then stained with 0.1% (w/v) Ponceau-S stain to
ensure successful transfer. Membranes were then blocked overnight in 5%
nonfat dry milk/PBS at room temperature. After blocking, membranes were
washed with 1% milk/PBS/0.1% Tween-20 and primary antibody was added at
appropriate working dilution, using 1% milk/PBS/0.1% T-20 as diluents. Primary
antibodies were diluted follows:
o PCNA monoclonal (Santa Cruz) 1:200
o native eNOS polyclonal (BD Biosciences) 1:200
o phospho-eNOS Ser1177 polyclonal (Santa Cruz) 1:200
o phospho-eNOS Thr495 polyclonal (Santa Cruz) 1:200
Primary antibody was allowed to incubate on the membrane for 1-2 hours at
room temperature or overnight at 4˚C. All subsequent washes and secondary
antibody dilution was carried out with 1%milk/PBS/0.1% T-20. Horseradish
peroxidase-conjugated secondary antibody (Southern Biotech) was allowed to
incubate at appropriate dilution on blot for 30 minutes at room temperature.
Visualization of membrane(s) was accomplished using ECL chemiluminescent
detection (GE Healthcare) and the Alpha-Innotech Fluorochem HD2 Gel Imaging
System.
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Densitometry analysis
Quantitative analysis of the western blots was performed using
densitometry analysis of the pixel densities of each visible band after
chemiluminescent staining. Initially, the local background of the band was
subtracted from the pixel density value, and then normalized to the protein
concentration loaded to give relative density.

Immunofluorescence Microscopy
Fibroblasts were trypsinized from a 100 mm dish when they reached ~70
-80% confluence and seeded onto 24-well plates containing one round
microscopic cover slip per well at a density of 4-8 x 105 cells/500 µl per well.
Cells were then allowed to incubate in CO2 incubator for 4-6 hours to adhere to
cover slips, or 24 hours if a higher confluence was desired. After incubation, and
if applicable, media was aspirated and replaced with fresh media containing
appropriate treatments. After the 24 hour treatment, cover slips were washed
with sterile PBS and fixed for 5 minutes using an ice cold mixture of 70%
methanol + 30% acetone. After fixation, cells were washed with PBS and blocked
overnight using 10% goat serum. The next day, the coverslips were washed four
times with PBS to remove excess blocking serum. eNOS polyclonal antibody (BD
Biosciences) was diluted 1:50 in 1% goat serum and incubated for one hour at
room temperature. After primary incubation, cells were washed three times each
with 1% milk/PBS/0.1% T-20. An IgG secondary antibody (Santa Cruz)
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conjugated to a Texas Red fluorophore was added at a 1:1000 dilution and the
cover slips were incubated for 30 minutes at room temperature. The washing
step was then repeated and cells were mounted on microscope slides using
Prolong Antifade (Invitrogen) and allowed to dry overnight at room temperature.
Low power images (20x objective) were visualized using the differential
interference contrast and DAPI filters of a Zeiss Axioplan-2 epifluorescent
microscope. Photographs were then captured using a high power (40x objective)
oil-immersion filter and an AxioCam MRm camera and associated software.
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RESULTS

eNOS localization is dependent upon cellular differentiation
Primary lung fibroblasts were isolated and cultured from Lewis rats and
used in all subsequent experiments. The cultured cells were grown under normal
growth conditions (DMEM media supplemented with 10% FBS), and then serum
starved for 24 hours to differentiate the cells. For simplification and consistency,
all cells grown under normal conditions will be referred to as protomyofibroblasts,
while those grown under serum-starvation conditions will be referred to as
myofibroblasts. All cells were between passages two and five when used. In
order to investigate eNOS localization under both normal and differentiated
conditions, fixed cells were probed with an anti-eNOS primary antibody and
Marina Blue-conjugated secondary antibody. As shown below in Figure 4A and
4B, eNOS is localized primarily in the nucleus of protomyofibroblasts yet in
myofibroblasts eNOS is expressed in the perinuclear/cytoplasmic region of the
cells (Figure 4C). Figure 4D are cells grown on coverslips and stained with the
secondary antibody only.
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Figure 4: eNOS localization is dependent upon cellular differentiation. Pulmonary
myofibroblasts were grown in DMEM supplemented with 10% FBS (A & B) or
DMEM with no FBS (C)‡ and then probed with an anti-eNOS primary antibody
and a Marina Blue-conjugated secondary antibody. D: Cells stained with
secondary antibody alone.
‡

It has previously been shown that serum starvation results in a protomyofibroblast to myofibroblast
transition characterized by skeletal protein expression (Rice & Leinwand, 2002).

eNOS localization and activity are correlated
Based on the observation that eNOS localization changes in response to
cell differentiation, we hypothesized that eNOS translocation would also correlate
with the catalytic synthesis of NO in either the nucleus or cytoplasm of the cell.
Intracellular levels of NO are qualitatively detectable by immunostaining fixed
cells with 4,5-diaminofluorescein-2 diacetate (DAF-2DA) (Leikert et al., 2001;
Schwendemann et al., 2008). DAF-2DA is a membrane-permeable fluorescein
chromophore that is hydrolyzed to DAF-2 and trapped within the cell where it
binds to NO and allows visualization by fluorescence microscopy. As shown in
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Figure 5A, treating protomyofibroblasts with 10 µM DAF-2DA stain (Sigma)
reveals NO synthesis to be localized primarily to the nucleus, while treated
myofibroblasts (Figure 5B) display NO in the perinuclear region of the cell
(experiments performed by Ms. Naomi Rowland). Previous data has suggested
that eNOS is regulated by multiple mechanisms, including Ca2+/calmodulin
binding (Boo et al., 2006). Therefore to investigate the role of Ca2+ on eNOS
activity in the cells, both protomyofibroblasts and myofibroblasts were also
treated with 1 mM of the calcium chelator EGTA. As shown in Figure 5 as well,
intracellular Ca2+ does influence eNOS activity and localization; most
significantly, the chelation of intracellular Ca2+ in protomyofibroblasts causes
eNOS translocation to mimic that of differentiated myofibroblasts by moving from
the nucleus to the perinuclear region (Figure 5C). Catalytic activity of eNOS in
myofibroblasts (Figure 5D) does not appear to be affected by EGTA treatment.
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Figure 5: eNOS localization and activity are coordinated A: Protomyofibroblasts
stained with DAF-2DA. B: Myofibroblasts stained with DAF-2DA C:
Protomyofibroblasts + 1 mM EGTA stained with DAF-2DA D: Myofibroblasts + 1
mM EGTA stained with DAF-2DA.

eNOS is expressed in the nucleus in both protomyofibroblasts and
myofibroblasts
In order to more thoroughly quantify eNOS localization and eventually
activity, fractionation and immunoblot analysis was used in cells grown under
normal and differentiated conditions. Initially, successful fractionation into nuclear
and cytoplasmic components was confirmed by probing western blots with an
antibody directed at PCNA (Figure 6a and 6b). Nuclear fractions show bands
around the 30 kDa ladder marking, correlating with the 35 kDa size of PCNA
(Figure 6a). Cytoplasmic fractions probed with anti-PCNA antibody show no
bands at the 35 kDa region, confirming cells were adequately separated into
nuclear and cytoplasmic fractions.
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Figure 6: Cellular fractionation is confirmed by presence of PCNA in the nucleus
A: (Nuclear fractions) B: (cytoplasmic fractions): Cytoplasmic fractions: Lane e:
purified eNOS; Lane 1: Myofibroblasts- untreated; Lane 2: Protomyofibroblastsuntreated; Lane 3: Myofibroblasts- + PMA; Lane 4: Protomyofibroblasts + PMA;
Lane 5: Myofibroblasts- + PMA & EGTA; Lane 6: Protomyofibroblasts + PMA &
EGTA

Following confirmation of successful fractionation, both nuclear and
cytoplasmic extracts were probed with an anti-eNOS polyclonal antibody. As
shown in Figure 7 lanes one and two, protomyofibroblasts and myofibroblasts
express eNOS in the nucleus. Densitometry analysis (Figure 8), followed by
normalization to protein concentration, suggests that nuclear eNOS expression
appears higher in differentiated myofibroblasts than protomyofibroblasts,
although the difference could not be statistically confirmed. Results are in
agreement with previous experiments showing nuclear staining in myofibroblasts,
and to a less extent protomyofibroblasts, although no cytoplasmic eNOS staining
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was observed for any sample tested (data not shown) when expression levels
were quantified by densitometry.
Previous investigations in our lab have shown the expression and activity
of eNOS can be regulated by increasing or decreasing the levels of intracellular
Ca2+, although it isn’t clear if Ca2+ is acting directly on eNOS or upstream through
the activation of Ca2+-regulated signaling pathways (unpublished results).
Indeed, it appears the expression and activity of eNOS can be regulated
independently of Ca2+ as well, via the phosphorylation of Ser1177 (Fleming et al.,
2001). Moreover, Ca2+-dependent, PKC agonist-induced activation of eNOS,
resulting in the phosphorylation of Thr495 in the CaM-binding domain of the
protein, has also been reported to downregulate expression and catalytic activity
of the protein (Chen et al., 1999).
To further investigate the role of upstream Ca2+ signaling pathways in
regulating eNOS localization, cells were treated with 10 µM of the PKC activator
PMA. Additionally as a control, 150 µM EGTA was added to the cells treated with
PMA to mitigate the effects of the agonist. In Figure 7, lanes three and four show
myofibroblasts and protomyofibroblasts, respectively, treated with PMA. Lanes
five and six show myofibroblasts and protomyofibroblasts treated with PMA and
EGTA.
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Figure 7: eNOS expression is differentially regulated by Ca2+ in
protomyofibroblasts versus myofibroblasts. Western blot showing nuclear
fractions of treated and untreated cells. Lane 1: Myofibroblasts, no treatment;
Lane 2: Protomyofibroblasts, no treatment; Lane 3: Myofibroblasts treated with
10 µM PMA; Lane 4: Protomyofibroblasts treated with 10 µM PMA; Lane 5:
Myofibroblasts treated with 10 µM PMA and 150 µM EGTA; Lane 6:
Protomyofibroblasts treated with 10 µM PMA and 150 µM EGTA. This blot
represents the results of one experiment.
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Figure 8: Densitometry analysis of Figure 7. Pixel densities normalized to local
background of each boxed lane (Figure 7) and amount of protein loaded per well,
grouped according to treatment. 1- Myofibroblasts, no treatment; 2Myofibroblasts + PMA; 3- Myofibroblasts + PMA & EGTA; 4Protomyofibroblasts, no treatment; 5- Protomyofibroblasts + PMA; 6Protomyofibroblasts + PMA & EGTA

Results indicate that when differentiated myofibroblasts are treated with
PMA, eNOS expression decreases (Figures 7 and 8). Chelation of Ca2+ results in
the return of normal eNOS expression levels. Protomyofibroblasts do not
respond the same way to PKC activation. eNOS expression is slightly increased
in response to PMA treatment in these cells
It is reported that eNOS becomes less active if phosphorylated on Thr495
by PKC (Chen et al., 1999), as Thr495 phosphorylation may interfere with CaM
binding to the enzyme at low Ca2+ concentrations. After probing our previous
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immunoblotted cell fractions with native eNOS the membranes were stripped of
their antibodies and a polyclonal enzyme specific for phospho-eNOS (Thr495) was
used to analyze whether or not this residue is phosphorylated in PMA-treated
pulmonary myofibroblasts. Results indicate that Thr495 is not phosphorylated in
either the cytoplasmic or nuclear fractions in either protomyofibroblasts or
myofibroblasts. Therefore this particular residue is not implicated in the
attenutation of activity or change in expression of the eNOS in our cells.It is
possible the polyclonal antibody was not specific to this residue, as it differs in its
primary sequence position among mammals expressing the enzyme (ex: bovine
eNOS is phosphorylated on Thr495, while human eNOS is phosphorylated on
Thr497). Phosphorylation on Ser116 has been demonstrated to be inhibited by the
PKC inhibitor calphostin (Kou et al., 2002), suggesting other residues are
regulated by PKC activation and warrant further investigation.
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Figure 9: Phospho-eNOS (Thr495) immunoblots of nuclear and cytoplasmic
fractions. Nuclear fractions (Figure 9A) reprobed with anti-phosphorylated eNOS
(Thr495). “L” indicates the ladder band and “e” indicates the purified eNOS used
as a control. Figure 9B indicates cytoplasmic fractions.
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DISCUSSION

In recent years, the theory of IPF as a disease consisting predominantly of
chronic and uncontrolled inflammation has largely been dismissed as being
inaccurate. While many interstitial lung diseases include an identifiable initial
inflammatory response to a damaging agent, many patients heal or show vast
improvement with anti-inflammatory therapies (Selman & Pardo, 2002). The
evolution of the initial inflammatory response to the fibroproliferative pathology
characteristic of IPF is largely indistinguishable upon lung biopsy to that of other
interstitial lung diseases. Moreover, there is little evidence to suggest true IPF
begins with an inflammatory response, or support for the theory that inflammation
is prominent in the early phases of IPF (Bjoraker et al., 1998). Indeed, the lack of
long-term beneficial response to anti-inflammatory drugs, corticosteroids, and
immunosuppressive agents among patients suggests the mechanism behind the
onset and fibroproliferative nature of IPF lies in a realm science just beginning to
to be understood.
The focus of current research into IPF has generally centered on it as
being a disease of fibroproliferation preceded by alveolar cell activation (Selman
& Pardo, 2002). Both of these factors have been shown to trigger a number of
chemokines/growth factors that induce fibroblast migration and proliferation, and
differentiation among myofibroblasts, and subsequent accumulation of ECM
(Ramos-Nino et al., 2003: IPF Supplement). It’s important to recognize that the
potential inflammation and fibroproliferation seen in IPF are two
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pathophysiologically distinct pathways independent of each other. Novel
treatments and anti-fibrotic therapies are currently in various stages of
preclinical/clinical development (de Andrade & Thannickal, 2009) and take aim at
the underlying fibroproliferation that is now known to be the hallmark of the
disease.
A consistent finding from the various studies into the cell biology, growthfactor/cytokine signaling, animal models, and human models of IPF is the
accumulation of the aggregates of myofibroblasts in the fibroblastic foci of the
tissue (Thannickal and Horowitz, 2006). Ample evidence exists showing the
development of apoptosis-resistant phenotypes of myofibroblasts are generated
during fibroblast/myofibroblast differentiation in disease models of IPF, with a
correlation among the extent of the fibrotic foci and increased rates of mortality.
Nitric oxide, generated by NOS, plays a substantial role as a signaling
molecule involved in physiological processes in the airway epithelium (Gaston et
al., 1994; Barnes, 1995). The endothelial isoform of NOS (eNOS) has been
demonstrated to be a key enzyme in endothelial tissue homeostasis,
angiogenesis, and remodeling. In the last few years, and in this present study,
the goal of our research lab has been to characterize and investigate the factors
regulating eNOS (as well as iNOS) expression and activity, including posttranslational modifications of the enzyme, protein-protein interactions, cofactors,
Ca2+/CaM influences, and phosphorylation.
There has been a large amount of research into the biochemical
properties of eNOS in a number of endothelial cell types, namely bovine aortic
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endothelial cells. Alternatively, there is little research into the enzyme’s
expression in mesenchymal cells such as pulmonary myofibroblasts, the focus of
this thesis. Indeed, a PubMed search of “nitric oxide” and “pulmonary
myofibroblast” yields only nine results, while one of “nitric oxide” “bovine aortic
endothelial cell” yields 174.
Nitric oxide has been shown to attenuate the epithelial-mesenchymal
transition induced by TGF-β in alveolar epithelial cells both in vivo and in vitro.
This feature is also seen in pulmonary tissue biopsies of those patients with lung
fibrosis secondary to myofibroblast-mediated excessive ECM deposition (VyasRead et al., 2006). Additionally, inhibition of NO synthesis has been shown to
increase accumulation of myofibroblasts and subsequent collagen deposition
(Pessanh et al., 2000).
This study presents a potential mechanism by which nitric oxide influences
myofibroblast accumulation by investigating the role of eNOS in the pulmonary
myofibroblast. eNOS knockout mice experience prolonged pulmonary fibrosis in
response to the profibrotic agent bleomycin, suggesting a correlation between
eNOS expression and myofibroblast regulation and/or apoptosis. We have
demonstrated eNOS is the primary NOS isoform expressed in pulmonary
myofibroblasts and the enzyme’s localization is dependent upon growth
conditions. Immunocytochemistry of prtotmyofibroblasts grown under normal
(10% FBS) conditions predominately show eNOS expression confined to the
nucleus, with little cytosolic staining. Myofibroblasts grown under serum-starved
conditions (0% FBS) show an increase in α-SMA and MyHC expression and
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mimic in vivo differentiated conditions (Rice and Leinwand, 2003). eNOS is
translocated from the nuclear to cytoplasmic regions under these highly
differentiated conditions (see Figure 4), although nuclear staining is still
observed, as shown in figure 7.
In epithelial cells, eNOS has been shown to translocate from the caveolae
to intracellular sites in a Ca2+- dependent manner (Goetz et al., 1999). I have
shown this too, is the case for pulmonary myofibroblasts. Removal of Ca2+ from
cells by the chelator EGTA mimics a differentiated state, with eNOS expression
largely confined to the perinuclear region. Previous research indicating increases
in cytoplasmic Ca2+ levels activates CaM, which binds to the canonical CaMbinding domain in eNOS to promote the alignment of the oxygenase and
reductase domains of the enzyme, leading to an increase in catalytic activity
(Sessa, 2004; Fleming et al., 2001). My data shows pulmonary myofibroblasts
respond oppositely to Ca2+ presence, with a decrease in basal catalytic activity
upon by the removal of Ca2+.
There is ample evidence that regulation of eNOS localization, and,
coordinately, activity is regulated via phosphorylation/dephosphorylation on
multiple serine, tyrosine, and threonine residues by various protein kinases and
phosphatases (Dimmeler et al., 1999; Gallis et al., 1999; Michell et al., 2001).
Neuronal NOS (nNOS) was the first NOS isoform to be identified as
phosphorylated at distinct sites by PKC, and PKC-dependent phosphorylation
decreased the level of enzyme activity (Bredt et al., 1992). We investigated the
role of PKC-dependent phosphorylation on eNOS localization and activity by
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treating cells with the known PKC activator PMA and immunoblotting fractionated
cell lysates for native eNOS and phospho-eNOS (Thr495). PKC activation by PMA
has previously been shown to inhibit eNOS activity in cultured cells (Davda et al.,
1994; Hirata et al., 1995). In Figure 9, we show that myofibroblasts treated with
PMA do indeed synthesize lower than basal levels of eNOS, with the additions of
EGTA mitigating this effect. Protomyofibroblasts do not appear to be affected by
PMA treatment in the same way showing slight increases in expression. By
DAF-2DA staining, we have been also able to show qualitatively that NO is also
present in the same cellular regions as eNOS. This work is in agreement with
recent work in our lab by Dr. Bethel Sharma who has able to quantify NO activity
in our cells grown under various conditions. NO production was measured
amperometrically using an NO electrode (Innovative Instruments, Inc) and
normalized to total cell count. Treatment with 10 µM PMA was found to lower NO
production to near basal levels of differentiated cells. Addition of EGTA to the
PMA-treated differentiated cells restored NO production, providing confirmation
that phosphorylation of eNOS by PKC is associated with a reduction in its
catalytic activity in pulmonary myofibroblasts. Thus, the changes in eNOS
expression in response to PKC activation (Figure 8) correlate with changes in the
catalytic activity of the protein (Figure 10). These finding are in accordance with
earlier data showing eNOS is a PKC substrate and PKC-mediated
phosphorylation mitigates eNOS activity (Tsukahara et al., 1993; Davda et al.,
1994., Hirata et al., 1995; Fleming et al., 2001).
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Figure 10: PKC-induced phosphorylation coordinates with activity

These past and present studies have aided in analyzing the role
nitric oxide plays as a signaling molecule in the pulmonary myofibroblast, a cell
model with little background work, but with important research and clinical
implications. With IPF being a disease of uncontrolled fibroproliferation, the
possibility of using agents that alter collagen synthesis or mitigate other fibrotic
responses are current focuses of first-line treatment for those unresponsive to
conventional therapies. With its ability to inhibit microtubule polymerization,
colchicine has been investigated in vitro and in animal models and demonstrated
an ability to suppress the release of macrophage-derived growth factor and
fibronectin by cultured alveolar macrophages from patients with sarcoidosis and
IPF (Rennard et al., 1988) Treatment with interferon-γ is another novel antifibrotic with potential benefits to those with IPF. Ziesche and colleagues have
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demonstrated interferon-γ inhibits the proliferation of lung fibrosis in a dosedependent manner and reduces the synthesis of protein in fibroblasts (Ziesche et
al., 1999). Future studies are needed to gain insight into the role nitric oxide
plays in the fibroproliferative properties of this cell as implicated in IPF. With the
number of existing NO donating or inhibiting pharmaceuticals, the NO pathway
could yield yet more treatment options for a disease that, thus far, has tragic
consequences.
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